NCT00210210 2025-09-19
KETAMINE
Institut Bergonié
Phase 3 Completed
Institut Bergonié
Peking University First Hospital
G1 Therapeutics, Inc.
University of Alabama at Birmingham
Alexandria University
Centro Nacional de Investigaciones Oncologicas CARLOS III
Alexandria University
Assiut University
University of California, San Diego
Tianjin Medical University Cancer Institute and Hospital
Hospital General Universitario Elche